Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the 'Investors & Media' page of Regeneron's website. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.

TARRYTOWN, N.Y., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42^nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.

About Regeneron
Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.
Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite^® technologies, such as VelocImmune^®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center^®, which is conducting one of the largest genetics sequencing efforts in the world. 

For additional information about Regeneron, please visit www.regeneron.com or follow  Regeneron on LinkedIn.

Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com                           
           
Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com

FAQ

What event is Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) presenting at?

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference.

When is the presentation scheduled?

The presentation is scheduled for Monday, January 8, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).

Where can the webcast be accessed?

The webcast can be accessed from the 'Investors & Media' page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.

How long will the webcast be available for replay?

A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.